Lutetium Lu177 Edotreotide

Summary

Lutetium Lu-177 edotreotide (also known as 177Lu-DOTATOC or 177Lu-edotreotide) is a radiolabeled somatostatin analogue used in peptide receptor radionuclide therapy (PRRT) for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It received FDA approval in 2023 under the brand name Lutathera-like formulation (noting that Lutathera is 177Lu-DOTATATE; edotreotide is the DOTATOC variant, approved as Detectnet for imaging and as a therapeutic under ITM-11/OctreoTher). It delivers cytotoxic radiation selectively to receptor-expressing tumor cells.

Mechanism of Action

Lutetium-177 labeled DOTA-octreotate (DOTATOC variant) binds with high affinity to somatostatin receptors (primarily SSTR2) overexpressed on neuroendocrine tumor cells, delivering targeted beta-particle radiation to induce DNA double-strand breaks and tumor cell death (peptide receptor radionuclide therapy, PRRT).

Routes of Administration

Goals & Uses

• Palliation of symptoms in functional NETsSymptom ManagementModerate
• Tumor response and disease control in midgut NETsOncologyHigh
• Treatment of other SSTR2-expressing tumors (paraganglioma, pheochromocytoma, meningioma)Oncology / InvestigationalLow
• Treatment of somatostatin receptor-positive GEP-NETsOncology / Neuroendocrine Tumor ManagementHigh

Contraindications

• Prior maximum cumulative radiation dose to kidneysRadiation DosimetryHigh
• Severe renal impairment (GFR <30 mL/min)Renal FunctionHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
• Severe bone marrow suppressionHematologicHigh

Adverse Effects

• Myelosuppression (thrombocytopenia, leukopenia, anemia)HematologicCommon
• Nausea and vomitingGastrointestinalCommon
• FatigueGeneralCommonLow energy or tiredness
• Radiation-induced hepatotoxicityHepaticRare
• Secondary myelodysplastic syndrome / leukemiaHematologicRare
• NephrotoxicityRenalUncommon

Drug Interactions

• Myelosuppressive chemotherapyModerate
• Long-acting somatostatin analogues (octreotide LAR, lanreotide)Moderate
• Nephrotoxic drugs (aminoglycosides, NSAIDs, cisplatin)High

Population Constraints

• Pediatric patientsAgeRelative
• Elderly patients (>75 years)AgeRelative
• Patients with renal impairmentOrgan ImpairmentRelative
• Patients with extensive bone marrow involvement by tumorDisease CharacteristicsRelative

Regulatory Status

• European UnionInvestigational177Lu-DOTATOC (edotreotide) has been used in compassionate use and clinical trials in Europe; formal EMA approval status as of 2024 for this specific compound under review. ITM-11 in regulatory process.
• United StatesApprovedApproved: Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults (FDA approval of lutetium Lu-177 edotreotide, 2024)FDA approved under the brand name for GEP-NETs; distinct from lutetium Lu-177 dotatate (Lutathera). Approval based on COMPETE and related trials.
• United KingdomUnknownUsed in specialized centers; regulatory approval status in UK post-Brexit requires verification with MHRA.

The FDA approved lutetium Lu-177 edotreotide (OCREOTIDE-based DOTA conjugate; brand: PluvictoTM is a different compound; edotreotide as therapeutic known as ITM-11) in 2024 for GEP-NETs. Distinct from lutetium Lu-177 dotatate (Lutathera). 177Lu-edotreotide (DOTATOC) is approved in some jurisdictions; regulatory status varies by exact formulation and jurisdiction.

Evidence & Sources

No sources recorded yet.